Darzalex (Johnson & Johnson) Drug Overview & Product Profiles 2017-2026 - ResearchAndMarkets.com

DUBLIN--()--The "Darzalex" report has been added to ResearchAndMarkets.com's offering.

Darzalex (daratumumab; Johnson & Johnson) targets the transmembrane glycoprotein CD38, which is highly expressed on malignant multiple myeloma cells, but expressed at low levels in other tissues.

By binding to this protein, Darzalex induces myeloma cell death by several different mechanisms including apoptosis and antibody- and complement-dependent cytotoxicity.

Key Topics Covered

  1. Drug Overview
  2. Product Profiles
  3. Darzalex : Multiple myeloma
  4. Darzalex : NHL: Mantle cell lymphoma (MCL)

List of Figures

Figure 1: Darzalex for multiple myeloma - SWOT analysis

Figure 2: The authors drug assessment summary of Darzalex for multiple myeloma

Figure 3: The authors drug assessment summary of Darzalex for multiple myeloma

Figure 4: Darzalex sales for multiple myeloma across the US, Japan, and five major EU markets, by country, 2017-26

Figure 5: Darzalex for mantle cell lymphoma - SWOT analysis

List of Tables

Table 1: Darzalex drug profile

Table 2: Darzalex pivotal trial data in multiple myeloma

Table 3: Darzalex early-phase trial data in multiple myeloma

Table 4: Darzalex Phase III trials in multiple myeloma

Table 5: Darzalex sales for multiple myeloma across the US, Japan, and five major EU markets, by country ($m), 2017-26

Table 6: Patients treated with Darzalex across the US, Japan, and five major EU markets, by country, 2017-26

Table 7: Darzalex drug profile

Table 8: Darzalex Phase II trial in mantle cell lymphoma

For more information about this report visit https://www.researchandmarkets.com/r/cpp2bm

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Oncology Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Oncology Drugs